GITNUXREPORT 2026

Drug Development Industry Statistics

Drug development is astronomically expensive with high failure rates despite massive global investment.

Sarah Mitchell

Senior Researcher specializing in consumer behavior and market trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Phase I trials take average 2.1 years to complete.

Statistic 2

Phase II trials average 2.5 years duration.

Statistic 3

Phase III trials last average 3.2 years.

Statistic 4

Overall clinical trial timeline is 6-7 years from Phase I to approval.

Statistic 5

85% of experimental drugs fail in clinical trials.

Statistic 6

Phase I success rate to Phase II is 63%.

Statistic 7

Phase II to Phase III success rate is 31%.

Statistic 8

Phase III to approval success rate is 58%.

Statistic 9

Over 1 million clinical trials registered globally since 2000.

Statistic 10

US hosts 45% of global clinical trials.

Statistic 11

Average Phase III trial enrolls 300-3000 patients.

Statistic 12

Oncology trials have 3.4% success rate from Phase I to approval.

Statistic 13

Infectious disease trials success rate 20.6%.

Statistic 14

Number of Phase I starts increased 8% YoY in 2022.

Statistic 15

Adaptive trial designs used in 20% of Phase II/III trials in 2022.

Statistic 16

Patient recruitment takes 30% of total trial time.

Statistic 17

Decentralized trials grew 5x since 2020.

Statistic 18

AI used in 25% of trial design processes in 2023.

Statistic 19

Average trial site activation time is 3-6 months.

Statistic 20

70% of trials are multinational.

Statistic 21

Rare disease trials enroll median 20 patients.

Statistic 22

Diversity in trials: 75% White, 8% Black participants in US.

Statistic 23

Cost of Phase III trial averages $20-50 million.

Statistic 24

Real-world evidence used in 15% of trials post-2020.

Statistic 25

Basket/umbrella trials increased 300% since 2015.

Statistic 26

Pediatric trials represent 5% of total trials.

Statistic 27

Vaccine trials success rate 33.4% Phase I to approval.

Statistic 28

Protein degraders (PROTACs) pipeline: 100+ candidates.

Statistic 29

mRNA therapeutics market to $127 billion by 2030.

Statistic 30

Cell and gene therapy approvals doubled since 2017.

Statistic 31

AI drug discovery investments $20 billion in 2022.

Statistic 32

CRISPR gene editing trials: 50+ active in 2023.

Statistic 33

Precision medicine market $110 billion in 2022.

Statistic 34

CAR-T therapies approved: 6 by FDA as of 2023.

Statistic 35

Organoid models used in 15% of preclinical studies 2023.

Statistic 36

Digital twins in trials piloted by 20 pharma companies.

Statistic 37

RNA interference (RNAi) drugs approved: 5 since 2018.

Statistic 38

Nanotechnology drug delivery systems in 10% new approvals.

Statistic 39

Microbiome therapeutics trials: 200+ ongoing.

Statistic 40

Quantum computing pilots for drug discovery by 5 big pharma.

Statistic 41

Wearables data in trials increased 400% post-COVID.

Statistic 42

Global pharma market size was $1.48 trillion in 2022.

Statistic 43

US pharma market share 45% of global at $675 billion in 2022.

Statistic 44

Biologics market projected to $500 billion by 2025.

Statistic 45

Oncology drugs generated $203 billion revenue in 2022.

Statistic 46

Top 10 pharma companies revenue $400 billion in 2022.

Statistic 47

Pfizer revenue $100.3 billion in 2022 driven by COVID vaccines.

Statistic 48

Roche sales CHF 63.3 billion in 2022.

Statistic 49

J&J pharma sales $52.1 billion in 2022.

Statistic 50

Merck revenue $59.3 billion in 2022.

Statistic 51

Novartis sales $45.4 billion in 2022.

Statistic 52

AbbVie revenue $58.1 billion in 2022.

Statistic 53

AstraZeneca sales $45.8 billion in 2022.

Statistic 54

Sanofi revenue €43.4 billion in 2022.

Statistic 55

GSK sales £29.3 billion in 2022.

Statistic 56

Bristol Myers Squibb revenue $46.2 billion in 2022.

Statistic 57

Eli Lilly sales $28.5 billion in 2022.

Statistic 58

Gilead revenue $27.1 billion in 2022.

Statistic 59

Amgen sales $26.3 billion in 2022.

Statistic 60

Generics market $100 billion in US 2022.

Statistic 61

Biosimilars market $20 billion globally in 2022.

Statistic 62

The average cost to bring a new drug to market is approximately $2.6 billion, including failure rates.

Statistic 63

Global pharmaceutical R&D spending reached $238 billion in 2022.

Statistic 64

R&D expenditure by top 20 pharma companies was $162 billion in 2021.

Statistic 65

Probability of success from Phase I to approval is 8.4% for all drugs.

Statistic 66

Cost per approved drug has risen to $1.3 billion out-of-pocket since 2010.

Statistic 67

Biopharma R&D investment hit $147 billion in 2020.

Statistic 68

Average R&D intensity (R&D/sales) for pharma is 19-20%.

Statistic 69

US biopharma firms invested $102 billion in R&D in 2021.

Statistic 70

Capitalized cost of a new drug development is $2,794 million.

Statistic 71

R&D spending grew 5.5% annually from 2017-2022.

Statistic 72

Pfizer's R&D spend was $11.4 billion in 2022.

Statistic 73

Roche invested CHF 13.4 billion in R&D in 2022.

Statistic 74

Novartis R&D budget was $10.7 billion in 2022.

Statistic 75

Merck & Co. spent $12.2 billion on R&D in 2022.

Statistic 76

J&J R&D expenditure was $14.9 billion in 2022.

Statistic 77

AstraZeneca R&D spend reached $8.1 billion in 2022.

Statistic 78

Sanofi invested €6.3 billion in R&D in 2022.

Statistic 79

GSK R&D budget was £5.0 billion in 2022.

Statistic 80

Bristol Myers Squibb spent $9.0 billion on R&D in 2022.

Statistic 81

Eli Lilly R&D investment was $7.6 billion in 2022.

Statistic 82

AbbVie R&D spend totaled $6.5 billion in 2022.

Statistic 83

Gilead Sciences invested $5.0 billion in R&D in 2022.

Statistic 84

Amgen R&D expenditure was $4.5 billion in 2022.

Statistic 85

Biogen spent $3.0 billion on R&D in 2022.

Statistic 86

Regeneron Pharmaceuticals R&D was $4.2 billion in 2022.

Statistic 87

Moderna invested $4.9 billion in R&D in 2022.

Statistic 88

BioNTech R&D spend was €2.0 billion in 2022.

Statistic 89

Vertex Pharmaceuticals R&D was $2.4 billion in 2022.

Statistic 90

Incyte Corporation invested $900 million in R&D 2022.

Statistic 91

Exelixis R&D spend was $500 million in 2022.

Statistic 92

FDA approved 37 new drugs in 2022.

Statistic 93

EMA approved 39 new medicines in 2022.

Statistic 94

Average FDA review time for standard drugs is 10 months.

Statistic 95

Priority review shortens FDA time to 6 months.

Statistic 96

55 novel drugs approved by FDA in 2021.

Statistic 97

Breakthrough Therapy designation granted to 98 drugs since 2012.

Statistic 98

Orphan Drug Designation for 600+ products annually.

Statistic 99

Accelerated Approval pathway used for 70% oncology drugs.

Statistic 100

FDA issued 50 complete response letters in 2022.

Statistic 101

PMDA Japan approved 40 new drugs in 2022.

Statistic 102

Health Canada approved 45 new drugs in 2022.

Statistic 103

TGA Australia approved 30 innovative medicines in 2022.

Statistic 104

20% of approvals via Real-Time Oncology Review in 2022.

Statistic 105

RMAT designation for 50+ cell/gene therapies since 2017.

Statistic 106

FDA warning letters to pharma firms: 15 in 2022.

Statistic 107

Post-approval changes require prior approval for 40% of submissions.

Statistic 108

EU conditional marketing authorization for 10 drugs in 2022.

Statistic 109

Fast Track designation for 150+ programs annually.

Statistic 110

ANDA approvals: 700+ generics by FDA in 2022.

Statistic 111

Biosimilar approvals reached 40 by FDA as of 2023.

Statistic 112

Global harmonization via ICH guidelines adopted by 7 regions.

Statistic 113

FDA user fee for NDA is $3.1 million in FY2023.

1/113

Sources

Trusted by 500+ publications

+497

Imagine a world where bringing a single new pill to your pharmacy shelf costs a staggering $2.6 billion, a high-stakes gamble in a global industry that poured over $238 billion into research and development last year alone.

Key Takeaways

The average cost to bring a new drug to market is approximately $2.6 billion, including failure rates.
Global pharmaceutical R&D spending reached $238 billion in 2022.
R&D expenditure by top 20 pharma companies was $162 billion in 2021.
Phase I trials take average 2.1 years to complete.
Phase II trials average 2.5 years duration.
Phase III trials last average 3.2 years.
FDA approved 37 new drugs in 2022.
EMA approved 39 new medicines in 2022.
Average FDA review time for standard drugs is 10 months.
Global pharma market size was $1.48 trillion in 2022.
US pharma market share 45% of global at $675 billion in 2022.
Biologics market projected to $500 billion by 2025.
mRNA therapeutics market to $127 billion by 2030.
Cell and gene therapy approvals doubled since 2017.
AI drug discovery investments $20 billion in 2022.

Drug development is astronomically expensive with high failure rates despite massive global investment.

Clinical Trials;,

Phase I trials take average 2.1 years to complete.
Phase II trials average 2.5 years duration.
Phase III trials last average 3.2 years.
Overall clinical trial timeline is 6-7 years from Phase I to approval.
85% of experimental drugs fail in clinical trials.
Phase I success rate to Phase II is 63%.
Phase II to Phase III success rate is 31%.
Phase III to approval success rate is 58%.
Over 1 million clinical trials registered globally since 2000.
US hosts 45% of global clinical trials.
Average Phase III trial enrolls 300-3000 patients.
Oncology trials have 3.4% success rate from Phase I to approval.
Infectious disease trials success rate 20.6%.
Number of Phase I starts increased 8% YoY in 2022.
Adaptive trial designs used in 20% of Phase II/III trials in 2022.
Patient recruitment takes 30% of total trial time.
Decentralized trials grew 5x since 2020.
AI used in 25% of trial design processes in 2023.
Average trial site activation time is 3-6 months.
70% of trials are multinational.
Rare disease trials enroll median 20 patients.
Diversity in trials: 75% White, 8% Black participants in US.
Cost of Phase III trial averages $20-50 million.
Real-world evidence used in 15% of trials post-2020.
Basket/umbrella trials increased 300% since 2015.
Pediatric trials represent 5% of total trials.
Vaccine trials success rate 33.4% Phase I to approval.

Clinical Trials;, Interpretation

The drug development pipeline is a grueling, decade-long gauntlet where most hopeful molecules meet their demise, yet the industry soldiers on with a mix of stubborn optimism, adaptive designs, and a dash of AI, all while trying to recruit more than just the usual suspects.

Innovation Trends

Protein degraders (PROTACs) pipeline: 100+ candidates.

Innovation Trends Interpretation

The Protein degrader pipeline is now overflowing with over 100 candidates, suggesting that while the science is elegantly complicated, the strategy is simply to throw a highly targeted kitchen sink at the problem until something sticks.

Innovation Trends;,

mRNA therapeutics market to $127 billion by 2030.
Cell and gene therapy approvals doubled since 2017.
AI drug discovery investments $20 billion in 2022.
CRISPR gene editing trials: 50+ active in 2023.
Precision medicine market $110 billion in 2022.
CAR-T therapies approved: 6 by FDA as of 2023.
Organoid models used in 15% of preclinical studies 2023.
Digital twins in trials piloted by 20 pharma companies.
RNA interference (RNAi) drugs approved: 5 since 2018.
Nanotechnology drug delivery systems in 10% new approvals.
Microbiome therapeutics trials: 200+ ongoing.
Quantum computing pilots for drug discovery by 5 big pharma.
Wearables data in trials increased 400% post-COVID.

Innovation Trends;, Interpretation

The pharmaceutical industry, now turbocharged by AI and CRISPR, is boldly reimagining medicine from the molecule up, promising a future where your car might be recalled but your cells get a precision upgrade.

Market Economics;,

Global pharma market size was $1.48 trillion in 2022.
US pharma market share 45% of global at $675 billion in 2022.
Biologics market projected to $500 billion by 2025.
Oncology drugs generated $203 billion revenue in 2022.
Top 10 pharma companies revenue $400 billion in 2022.
Pfizer revenue $100.3 billion in 2022 driven by COVID vaccines.
Roche sales CHF 63.3 billion in 2022.
J&J pharma sales $52.1 billion in 2022.
Merck revenue $59.3 billion in 2022.
Novartis sales $45.4 billion in 2022.
AbbVie revenue $58.1 billion in 2022.
AstraZeneca sales $45.8 billion in 2022.
Sanofi revenue €43.4 billion in 2022.
GSK sales £29.3 billion in 2022.
Bristol Myers Squibb revenue $46.2 billion in 2022.
Eli Lilly sales $28.5 billion in 2022.
Gilead revenue $27.1 billion in 2022.
Amgen sales $26.3 billion in 2022.
Generics market $100 billion in US 2022.
Biosimilars market $20 billion globally in 2022.

Market Economics;, Interpretation

The pharmaceutical industry is a staggeringly large ecosystem where a single therapeutic area like oncology can be a Fortune 500 company unto itself, yet the scramble for the next blockbuster drug means even the giants live or die by a single scientific breakthrough.

R&D Costs;,

The average cost to bring a new drug to market is approximately $2.6 billion, including failure rates.
Global pharmaceutical R&D spending reached $238 billion in 2022.
R&D expenditure by top 20 pharma companies was $162 billion in 2021.
Probability of success from Phase I to approval is 8.4% for all drugs.
Cost per approved drug has risen to $1.3 billion out-of-pocket since 2010.
Biopharma R&D investment hit $147 billion in 2020.
Average R&D intensity (R&D/sales) for pharma is 19-20%.
US biopharma firms invested $102 billion in R&D in 2021.
Capitalized cost of a new drug development is $2,794 million.
R&D spending grew 5.5% annually from 2017-2022.
Pfizer's R&D spend was $11.4 billion in 2022.
Roche invested CHF 13.4 billion in R&D in 2022.
Novartis R&D budget was $10.7 billion in 2022.
Merck & Co. spent $12.2 billion on R&D in 2022.
J&J R&D expenditure was $14.9 billion in 2022.
AstraZeneca R&D spend reached $8.1 billion in 2022.
Sanofi invested €6.3 billion in R&D in 2022.
GSK R&D budget was £5.0 billion in 2022.
Bristol Myers Squibb spent $9.0 billion on R&D in 2022.
Eli Lilly R&D investment was $7.6 billion in 2022.
AbbVie R&D spend totaled $6.5 billion in 2022.
Gilead Sciences invested $5.0 billion in R&D in 2022.
Amgen R&D expenditure was $4.5 billion in 2022.
Biogen spent $3.0 billion on R&D in 2022.
Regeneron Pharmaceuticals R&D was $4.2 billion in 2022.
Moderna invested $4.9 billion in R&D in 2022.
BioNTech R&D spend was €2.0 billion in 2022.
Vertex Pharmaceuticals R&D was $2.4 billion in 2022.
Incyte Corporation invested $900 million in R&D 2022.
Exelixis R&D spend was $500 million in 2022.

R&D Costs;, Interpretation

The pharmaceutical industry operates a multi-billion-dollar casino where the house edge is a brutal 91.6%, but the jackpot for a winning ticket is measured in human lives.

Regulatory Approvals;,

FDA approved 37 new drugs in 2022.
EMA approved 39 new medicines in 2022.
Average FDA review time for standard drugs is 10 months.
Priority review shortens FDA time to 6 months.
55 novel drugs approved by FDA in 2021.
Breakthrough Therapy designation granted to 98 drugs since 2012.
Orphan Drug Designation for 600+ products annually.
Accelerated Approval pathway used for 70% oncology drugs.
FDA issued 50 complete response letters in 2022.
PMDA Japan approved 40 new drugs in 2022.
Health Canada approved 45 new drugs in 2022.
TGA Australia approved 30 innovative medicines in 2022.
20% of approvals via Real-Time Oncology Review in 2022.
RMAT designation for 50+ cell/gene therapies since 2017.
FDA warning letters to pharma firms: 15 in 2022.
Post-approval changes require prior approval for 40% of submissions.
EU conditional marketing authorization for 10 drugs in 2022.
Fast Track designation for 150+ programs annually.
ANDA approvals: 700+ generics by FDA in 2022.
Biosimilar approvals reached 40 by FDA as of 2023.
Global harmonization via ICH guidelines adopted by 7 regions.
FDA user fee for NDA is $3.1 million in FY2023.

Regulatory Approvals;, Interpretation

The regulatory engines are clearly running hot, approving a steady stream of new treatments through a complex maze of expedited pathways, but the high costs, frequent rejections, and tight post-approval reins remind us that this medical marathon is run on a track paved with both gold and caution.